Medtronic Archives - Page 35 of 59 - Medical Design Sourcing

How medtech fared in the first waves of the pandemic

[Photo by Martin Sanchez on Unsplash]

Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data.

Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial toll on the industry.

To compare performance before and during the pandemic, MDO used the financial data that we’ve historically gathered to rank our Big 100 companies in the last three years. The majority of these companies reported full-year results for 2020; others operate on a fiscal year and reported annual results in the first half of 2021.

Some companies are not in this year’s Big 100 but were included in the analysis because they were ranked in pre…

How some diabetes tech companies are honoring National Diabetes Month

World Diabetes Day (Nov. 14) may have passed, but it remains National Diabetes Month through the end of November.

A number of companies developing some of the most intriguing innovations in diabetes care have also stepped forward this month to organize awareness-raising efforts for the metabolic disease.

Here are some steps a handful of diabetes technology developers have made to try and bring more attention to diabetes management:

Get the full story at our sister site, Drug Delivery Business News.

7 diabetes treatment innovations to look out for on World Diabetes Day

World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes.

This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease.

Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains a vital part of the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists involved in discovering insulin as a treatment for diabetes.

However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for managing and treating diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:

Next>>

7 diabetes treatment innovations to look out for on World Diabetes Day

World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes.

This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease.

Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains a vital part of the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists involved in discovering insulin as a treatment for diabetes.

However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for managing and treating diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:

Next>>

FDA clears Medtronic’s PillCam system for remote endoscopy procedures

[Image from Medtronic]Medtronic (NYSE:MDT) announced today that it received FDA 510(k) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures.

PillCam SB3 @Home program works with Amazon logistics to ensure timely and accurate results for patients undergoing remote endoscopy procedures from the comfort of their own homes, according to a news release.

The platform offers a telehealth option for the direct visualization and monitoring of the small bowel. Medtronic said it helps to better detect lesions not detected by upper and lower endoscopy that may indicate Crohn’s disease, locate obscure bleeding or identify sources of iron deficiency anemia (IDA).

PillCam SB3 is delivered straight to a patient and, through a telehealth appointment, a provider guides the patient through the remote procedure and the patient returns the data recorder and sensor belt to Medtronic once the procedure is complete. Over the course of the eight-hour…

Medtronic appoints 4 new members to executive team

Medtronic (NYSE:MDT) announced today that it made four new appointments to its executive team, including strategy and innovation heads.

Both effective today, Bob Hopkins became Medtronic’s Head of Global Strategy and Mei Jiang became the new Global Digital Innovation Leader. Mira Sahney will become President of the pelvic health operating unit effective Dec. 6, 2021, while Harry “Skip” Kiil will become President of the cranial and spinal technologies (CST) operating unit, effective Jan. 4, 2022, according to a news release.

“We’re making bold moves to lead in healthcare technology and be a destination for world-class talent,” Medtronic Chairman & CEO Geoff Martha said in the release. “These executive appointments bring outside-in thinking, new skills and capabilities, and diverse perspectives to our already talented leadership team – and will continue to power Medtronic’s transformation.”

Hopkins …

7 diabetes treatment innovations to look out for on World Diabetes Day

World Diabetes Day — Nov. 14 — centers around raising awareness for those who live every day with diabetes.

This year, that aim remains the same, and medical technology companies all over the world continue to look for ways to help manage the metabolic disease.

Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists who helped to discover insulin as a treatment for diabetes.

However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for helping to manage and treat diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:

Next>>

The 100 largest medical device companies in the world

Nearly half a trillion dollars — $421 billion to be exact — that’s how much the world’s 100 largest medical device companies brought in over the past year amid the COVID-19 pandemic.

That’s one of the big takeaways from the Big 100, MassDevice and Medical Design & Outsourcing‘s annual analysis of the worlds’ 100 largest medtech companies. (Check out the full Big 100 rankings here.)

Aggregate revenue for approximately 100 of the largest medical technology companies dropped 1.2% in 2020 compared to 2019. But that’s not bad considering that the worst pandemic in a century was taking place, sparking a global recession in its wake.

Some medtech businesses that played critical roles fighting the pandemic — such as 3M’s Health Care segment and Hologic — even saw revenues increase and rose in the Big 100 rankings as a result.

Check out the full Big 100 rankings here>>

The 100 largest medical device companies in the world

Nearly half a trillion dollars — $421 billion to be exact — that’s how much the world’s 100 largest medical device companies brought in over the past year amid the COVID-19 pandemic.

That’s one of the big takeaways from the Big 100, MassDevice and Medical Design & Outsourcing‘s annual analysis of the worlds’ 100 largest medtech companies. (Check out the full Big 100 rankings here.)

Aggregate revenue for approximately 100 of the largest medical technology companies dropped 1.2% in 2020 compared to 2019. But that’s not bad considering that the worst pandemic in a century was taking place, sparking a global recession in its wake.

Some medtech businesses that played critical roles fighting the pandemic — such as 3M’s Health Care segment and Hologic — even saw revenues increase and rose in the Big 100 rankings as a result.

Check out the full Big 100 rankings here>>

What is renal denervation? Medtronic Coronary and RDN President Jason Weidman explains

Jason Weidman is a Medtronic SVP and president of its coronary and renal denervation business. [Photo courtesy of Medtronic]Medtronic (NYSE:MDT) continues clinical trials of its Symplicity Spyral renal denervation (RDN) system for treating hypertension. The hope now is to win FDA approval in 2023.

To better understand the technology behind what Medtronic leaders expect to become a multibillion-dollar business, Medical Design & Outsourcing spoke with Jason Weidman, Medtronic SVP and president of the coronary and renal denervation business, which is part of Medtronic’s cardiovascular portfolio.

Get the full story at our sister site, Medical Design & Outsourcing.

What is renal denervation? Medtronic Coronary and RDN President Jason Weidman explains

Jason Weidman is a Medtronic SVP and president of its coronary and renal denervation business. [Photo courtesy of Medtronic]

As Medtronic (NYSE:MDT) continues clinical trials of its Symplicity Spyral renal denervation (RDN) system for treating hypertension, the Fridley, Minnesota-based medical device maker now hopes to win FDA approval in 2023.

To better understand the technology behind what Medtronic leaders expect to become a multibillion-dollar business, Medical Design & Outsourcing spoke with Jason Weidman, Medtronic senior vice president and president of the coronary and renal denervation business, which is part of Medtronic’s cardiovascular portfolio. (We’ve edited this conversation for brevity and clarity.)

MDO: What’s the simplest way to explain renal denervation?

Weidman: The basic idea is that your kidneys are part of the body’s blood pressure control mechanis…

Medtronic reports promising early data for transfemoral delivery of its Intrepid TMVR

Medtronic (NYSE:MDT) this week touted data for its Intrepid self-expanding transcatheter mitral valve replacement (TMVR) system.

Early data from 15 patients in an early feasibility study was presented as late-breaking clinical science at the 33rd Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. The study evaluated patients with severe, symptomatic mitral valve regurgitation (MR), utilizing the transfemoral access route.

Get the full story at our sister site, Medical Tubing & Extrusion.